US Health Officials Question AstraZeneca Vaccine Data and Efficacy

whh3 writes: The NIAID issued a statement early Tuesday saying that they had concerns about the data that AstraZeneca included in their Monday-morning release touting the effectiveness of their Covid-19 vaccine. Slashdot reader phalse phace has shared additional information via The Hill. They write: U.S. health officials from the Data and Safety Monitoring Board issued an unusual statement that it was "concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial." This comes less than 24 hours after AstraZeneca said its vaccine had an "efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization" and a week after several countries suspended dosing of the vaccine due to concerns of dangerous blood clots. The Data and Safety Monitoring Board "expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data." As an oversight committee, the Data and Safety Monitoring Board helps regulate and evaluate clinical trials of new medicines to ensure accuracy and adherence to protocols. In a statement released early Tuesday morning, AstraZeneca said the interim results it announced on Monday were current as of Feb. 17. The latest development could throw a wrench in AstraZeneca's plan to seek the U.S. Food and Drug Administration's emergency use authorization for its vaccine. Additional coverage: The New York Times

Read more of this story at Slashdot.

from Slashdot https://ift.tt/3fanq4a

Share on FacebookPlus on Google+

SUBSCRIBE TO OUR NEWSLETTER